NAL ER
NAL04-201
Phase 2 small_molecule completed
Quick answer
NAL ER for Refractory Chronic Cough is a Phase 2 program (small_molecule) at Trevi Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Trevi Therapeutics
- Indication
- Refractory Chronic Cough
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed